Triple therapy aims to turn inoperable bowel cancer into surgical candidates
NCT ID NCT07446465
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining chemotherapy (FOLFOX), a targeted drug (fruquintinib), and an immunotherapy (serplulimab) can shrink advanced colorectal cancer enough to allow surgery. About 42 adults with a specific genetic type (pMMR/MSS) who have not had prior treatment will receive the combination. The goal is to see if more patients can become eligible for surgery and how well the tumors respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (LOCALLY ADVANCED OR METASTATIC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Xuhui, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.